ReviewCurrent drug delivery2026
Advances in Nanostructured Lipid Carriers for Colorectal Cancer Treatment: A Comprehensive Review.
Review in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As colorectal cancer is the third most common cancer globally, this study aimed to improve colorectal cancer treatment using nanostructured lipid carriers (NLCs) for drug delivery by overcoming the current drawbacks, improving therapeutic effectiveness, achieving site-specific delivery, and implementing controlled drug administration to mitigate systemic side effects. Based on the literature, it has been observed that the optimal drug size and zeta potential range depend on the drug formulation's targets and features. These ranges are determined through optimization and characterization. The particle size ranges from 10 to 200 manometers, and the zeta potential values range from -30 mV to +30 mV. Optimal formulations should have uniform spherical morphology and compatibility with biological entities. This paper provides an in-depth analysis of nanocarrier research and findings. This article offers a thorough synopsis of the latest research and findings on nanocarriers, offering a valuable understanding of their development.
Indexed as
Identifiers
40207826What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.